Dublin, April 22, 2021 (GLOBE NEWSWIRE) -- The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2021" report has been added to ResearchAndMarkets.com's offering.
Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.
Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 100 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells.
The cargo contained within exosomes can offer prognostic information for range of diseases - including cardiovascular, renal, neurodegenerative, and metabolic diseases - as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.
Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient's response to a specific course of treatment.
Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient's exosomes can be isolated, modified with the appropriate siRNA or protein and then injected back into the patient for treatment. There are also many approaches being researched for creating drug-loaded exosomes. Furthermore, exosomes can often exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.
For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. Fifteen years ago in 2006, there were only 76 articles published about exosomes on PubMed.gov. Today, there an astounding 17,850 articles published about exosomes on PubMed.gov, of which the vast majority were released in the past five years.
When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and China comes in second place. When the term "exosome" is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author. When the term "extracellular vesicles" is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Professor Giovanni Camussi.
This global market report explores growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. It reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials and highlights information about exosome industry partnerships, merger and acquisition (M&A) activity, and financing events. It features company profiles for 107 global competitors from across the exosome marketplace. Importantly, it presents market size determinations by market segment with forecasts through 2028.
Today in 2021, the exosomeindustry is witnessing:
A surging number of scientific papers investigating exosomes and their applications
Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics
Swelling appetite among investors for exosome technology
An increasingly competitive IP environment
A diverse range of co-development partnerships
Proliferating numbers of exosome competitors in all major life science markets worldwide
Key Topics Covered:
1. REPORT OVERVIEW
2. EXOSOMES: AN OVERVIEW
3. EXOSOME RESEARCH
4. EXOSOMES: CLINICAL TRIALS LANDSCAPE
5. CURRENT STATUS OF EXOSOME MANUFACTURING
6. CURRENT STATUS OF EXOSOME INDUSTRY
7. EXOSOME ISOLATION APPROACHES
8. EXOSOME ENGINEERING: A NEW PLATFORM
9. MSC-DERIVED EXOSOMES IN REGENERATIVE MEDICINE
10. DIAGNOSTIC APPLICATIONS OF EXOSOMES
11. THERAPEUTIC APPLICATIONS OF EXOSOMES
12. APPLICATIONS OF EXOSOMES IN VACCINE DEVELOPMENT
13. EXOSOME RESEARCH TOOLS
14. EXOSOME MARKET ANALYSIS
15. PROFILES OF EXOSOME MARKET COMPETITORS
Aethlon Medical, Inc.
AgeX Therapeutics, Inc.
Alexerion Biotech Corp.
AMS Biotechnology, Ltd. (AMSBIO)
Avalon GloboCare Corp.
Aviva Systems Biology
BARD1 Life Sciences, Ltd.
Beckman Coulter Life Sciences
Biological Dynamics, Inc.
BioRegenerative Sciences, Inc.
BrainStorm Cell Therapeutics
BreStem Therapeutics, Inc.
Cell Care Therapeutics
Cell Factory BVBA/Esperite NV
Cell Guidance Systems, Ltd.
Cellarcus Biosciences, Inc.
Creative Medical Technology Holdings, Inc.
Cusabio Technology LLC
Evomic Science, LLC
Evox Therapeutics, Ltd.
ExoCan Healthcare Technologies, Pvt. Ltd.
ExoCoBio, Co., Ltd.
Exosome Diagnostics, Inc.
GenWay Biotech, Inc.
Guardant Health, Inc.
HansaBioMed Life Sciences, Ltd.
Hitachi Chemical Diagnostics, Inc.
ILIAS Biologics, Inc.
Innocan Pharma Corporation
Innovex Therapeutics, S.L.
Invent Biotechnologies, Inc.
Izon Science, Ltd.
Kimera Labs, Inc.
Leading Biology, Inc.
LifeSpan BioSciences, Inc.
Lonza Group Ltd.
Miltenyi Biotec B.V. & Co. KG
New England Peptide, Inc.
Norgen Biotek Corp.
Novus Biologicals, LLC
Oasis Diagnostics Corp.
OriGene Technologies, Inc.
Paracrine Therapeutics, Pvt. Ltd.
Stemcell Medicine, Ltd.
System Biosciences, LLC
Theoria Science, Inc.
Thermo Fisher Scientific
TransGen Biotech, Co., Ltd.
TriArm Therapeutics, Co., Ltd.
United Therapeutics Corp.
Vesigen Therapeutics, Inc.
VivaZome Therapeutics, Pvt. Ltd.
YMIR Genomics LLC
For more information about this report visit https://www.researchandmarkets.com/r/wfb5ah
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900